Skip to Main Content

The contours of the latest battle over patents on the CRISPR genome editing technology are becoming a little clearer: In a decision released Monday evening, the U.S. patent office told the Broad Institute, on one side, and the University of California and its allies, on the other, what they’ll be allowed to fight about.

And in tennis terms, it’s advantage, Broad.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED